THE INFLUENCE OF QUINAPRIL THERAPY ON STATEDLY ADAPTIVE STATUS OF PATIENTS WITH I st FUNCTIONAL CLASS CHRONIC CARDIAC FAILURE
The research covered 49 patients with 1st functional class chronic cardiac failure with underlying hypertensive disease of I-I stages, including 24 women and 25 men the average age of whom was 52,5 1,4 y. o. Treadmill activity, echocardiography and 6-minute walk test was carried out initially and within six months of Quinapril therapy (Accupro of Pfaizer, USA production, daily doze is 17,3 4,7 mg). For the purpose of fair quantitative estimation of statedly adaptive status of an organism cardio-respiratory synchronism trial has been executed. The Quinapril monotherapy of patients with 1st functional class chronic cardiac failure with underlying I-I stage hypertensive disease during 6 months reliably improved the structural and functional status of myocardium, advanced effort tolerance, and positively affected statedly adaptive capacities of the examined patients. Statedly adaptive capacities are medicated by interaction of two peripheral divisions of vegetative nervous system, the sympathetic and the parasympathetic one. The Quinapril, ATE (angiotensine transforming enzyme) inhibitor improved functional state of patients due to regress of cardiovascular remodeling and appropriate impact on sympathetic-parasympathetic imbalance evolving under chronic cardiac failure.